Acumen Pharmaceuticals Currently Expects To Exercise Its Option To License Two Compounds Developed As Part Of Its Collaboration With JCR Pharma During Q2 Of 2026

Benzinga Newsdesk www.benzinga.com Neutral 53.3%

Neg 0% Neu 53.3% Pos 0%

Comments

No comments yet. Be the first!